News | Cardiovascular Ultrasound | April 29, 2022

Study Evaluates AI Software that Aids Novice Users Performing Echocardiogram

Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to participate in the clinical trial.

Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to join a clinical trial studying machine-learning software designed to help novice users perform an echocardiography exam.

The study will evaluate the UltraSight Echocardiographic Guidance software.


April 29, 2022 – Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to join a clinical trial studying machine-learning software designed to help novice users perform an echocardiography exam.

“Echocardiography, or an ultrasound of the heart, is the most widely used imaging method in cardiology,” said Bijoy Khandheria, MD, Advocate Aurora Research Institute’s principal investigator for the study. “It is more portable, less expensive and has fewer side effects than other cardiac imaging technologies. However, echocardiography requires intensive training in order to obtain accurate results.”

The clinical trial evaluates the safety and efficacy of UltraSight Echocardiographic Guidance (USEG) software. The software is a machine-learning, downloadable mobile application that uses artificial intelligence to provide real-time guidance on how to position the transducer, or wand-like device used to obtain the ultrasound images, when performing an echocardiogram. It is designed to help medical professionals who do not have advanced training in echocardiography obtain diagnostic-quality images of the heart.

“Echocardiography is useful for diagnosing a wide range of cardiac conditions, and the ultrasound images it produces can be evaluated in real time, making it valuable in a variety of settings, from outpatient clinics to emergency departments,” said Laura Wrona, MSN, director of cardiovascular clinical trials research. “By guiding novice users – perhaps a medical resident, nurse practitioner or physician assistant – through a limited exam, the USEG software has the potential to help health care providers more quickly detect urgent findings regarding the heart’s function.”

Participants will be asked to join the study because they have a cardiac echocardiogram scheduled as part of their standard medical care. If they consent to join the study, each participant will first undergo their scheduled standard of care echocardiogram. Then, as part of the research study, an expert sonographer will conduct an echocardiogram without assistance from the USEG software followed by a novice user who will receive guidance from the USEG software. Researchers will then assess the quality of the images obtained.

The study will evaluate the USEG software, not the device used to perform the echocardiogram. The transducer used to obtain the ultrasound images in this study is already approved by the U.S. Food and Drug Administration for commercial use. The USEG software is designed to work with any transducer.

The clinical trial, “Study for the assessment of the quality of echocardiographic clips,” is sponsored by UltraSight, developer of the USEG software.

To learn more about Advocate Aurora’s research, visit aah.org/research.


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now